Comparative Pharmacology
Head-to-head clinical analysis: ILLUCCIX versus PROSTASCINT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILLUCCIX versus PROSTASCINT.
ILLUCCIX vs PROSTASCINT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle, leading to bronchodilation.
PROSTASCINT is a murine monoclonal antibody fragment (capromab pendetide) conjugated to the chelating agent glycyl-tyrosyl-lysyl-diethylenetriaminepentaacetic acid (GYK-DTPA) and labeled with indium-111. It binds to the intracellular epitope of prostate-specific membrane antigen (PSMA) expressed on prostate epithelial cells and is used for imaging prostate cancer.
10 mg orally once daily, with or without food.
5 mCi (185 MBq) intravenously over 5 minutes, single dose.
None Documented
None Documented
Terminal elimination half-life is 4–6 hours in patients with normal hepatic function; may be prolonged in hepatic impairment.
Terminal elimination half-life: 2.6 ± 0.7 days (requires 2 weeks for complete clearance; used for radioimmunodetection within 5–7 days post-injection)
Primarily hepatic metabolism with renal elimination of metabolites: ~30% unchanged in urine, <5% in feces.
Renal: ~90% (predominantly as intact tracer), Fecal: <5%
Category C
Category C
Radiopharmaceutical Diagnostic Agent
Radiopharmaceutical Diagnostic Agent